Effectiveness of leech therapy in osteoarthritis of the knee: a randomized, controlled trial
Michalsen A, Klotz S, Lüdtke R, Moebus S, Spahn G, Dobos GJ (2003) · Annals of Internal Medicine · n=51
Perfil del estudio
- Diseño
- single-center, open-label, randomized controlled trial (Essen, Germany)
- Tamaño de la muestra (n)
- 51
- Intervención
- Single session of 4-6 Hirudo medicinalis leeches applied around the knee for 60-80 minutes
- Comparador
- Topical diclofenac gel applied twice daily for 28 days (standard NSAID care)
- Punto final primario
- WOMAC pain subscale score (Western Ontario and McMaster Universities Osteoarthritis Index) at day 7
- Resultado primario
- WOMAC pain reduction 64% in leech group vs 18.5% in diclofenac group at day 7 (mean difference 24.4 points on 100-point VAS, 95% CI 14.7-34.0, p<0.001); benefit sustained through day 91
- Effect size (Cohen's d)
- 1.4
- Duración del seguimiento
- 91 days
- PMID
- 14597456
Hallazgos clave
- WOMAC pain dropped 64% in leech arm vs 18.5% in topical diclofenac arm at day 7 (p<0.001)
- Function (WOMAC physical function subscale) improved significantly in leech group through day 28
- Quality-of-life gains (SF-36 bodily pain, physical functioning) persisted to day 91
- Single 60-80 minute session produced an effect size larger than 4 weeks of NSAID gel
- No serious adverse events; mild local pruritus in 3 leech patients self-resolved within 7 days
Limitaciones
- Open-label design (no sham control) — placebo and expectancy effects not separable
- Single center (Essen Department of Naturopathy) — generalizability untested
- Small sample (n=51) limits subgroup analysis
- Diclofenac gel comparator chosen for safety, not maximum effect — could underestimate NSAID efficacy
- No biochemical markers to verify proposed mechanisms (anti-inflammatory, analgesic compounds)
Implicaciones clínicas
Michalsen 2003 is the foundational modern RCT for hirudotherapy in knee OA and established the field's signature effect size: a single session producing pain reduction equivalent to or exceeding 4 weeks of standard topical NSAID care. The trial directly motivated subsequent confirmatory work (Andereya 2008, Lauche 2014) and is cited in the German S3 guidelines for non-pharmacologic OA management. Clinicians should view Michalsen 2003 as proof-of-concept that justifies offering leech therapy to NSAID-intolerant or NSAID-contraindicated knee OA patients, while recognizing that the open-label design means a portion of the effect likely reflects ritual and expectancy. For US clinicians, this trial is the most commonly cited single source supporting the FDA 510(k) K040187 clearance pathway.
Estudios relacionados
Leech therapy for symptomatic treatment of knee osteoarthritis: results and implications of a pilot study
Andereya S, Stanzel S, Maus U, Mueller-Rath R, Mumme T, Miltner O (2006)
Comparison of modern leech therapy with intra-articular hyaluronic acid injections for symptomatic relief of knee osteoarthritis
Andereya S, Stanzel S, Maus U, Mueller-Rath R, Mumme T, Miltner O, Andereya S (2008)
A systematic review and meta-analysis of medical leech therapy for osteoarthritis of the knee
Lauche R, Cramer H, Langhorst J, Dobos G (2014)
Effects of leech therapy on knee osteoarthritis: a randomized clinical trial in an Iranian population
Khoshnevisan A, Sahebkar A, Mohammadpour AH, Mosaffa-Jahromi M (2022)